Antisoma and BioInvent Sign BC-1 Monoclonal Antibody Manufacturing Agreement

Apr 11, 2001, 01:00 ET from Antisoma plc

    LONDON and LUND, Sweden, April 11 /PRNewswire/ -- Antisoma plc (LSE:ASM,
 EASD:ASOM) and BioInvent International AB today announce an agreement for the
 production of muBC-1, a murine monoclonal antibody.  muBC-1 will be used by
 Antisoma to develop a radiolabelled product, AngioMab, which is a potential
 anti-angiogenic treatment for targeted cancer therapy.
     Under the agreement, BioInvent, through its subsidiary BioInvent
 Production AB, will carry out process development and GMP (Good Manufacturing
 Practice) production of the antibody ready for radiolabelling, to meet both
 European (EMEA) and US (FDA) standards for clinical studies.
     It is currently expected that AngioMab will start Phase I human clinical
 studies at the end of 2001.  The product will be initially developed for
 intracranial delivery to treat glioblastoma multiforme, an aggressive form of
 brain cancer.  These tumours are often unresponsive to chemotherapy and are
 usually treated by surgery and radiotherapy.  There is a significant need to
 improve the low response and poor survival rates following standard therapy.
     Commenting on the agreement, Glyn Edwards, Chief Executive of Antisoma,
 said:
     "We have worked with BioInvent for more than four years and are pleased to
 extend the collaboration to a second product.  BioInvent have manufactured
 clinical supplies for our Phase III ovarian cancer study with pemtumomab.
 With the ever increasing number of biologicals entering clinical trials, the
 development of a sound relationship with BioInvent and the securing of
 manufacturing capacity is paramount to our bringing new molecules forward for
 clinical trials.  Antisoma aims to have at least one more product in clinical
 development by the end of this year, and securing this agreement for AngioMab
 takes us a step closer to our goal. "
     Cristina Glad, President of BioInvent Production AB, added:
     "Antisoma's decision to place the order for process development and GMP
 manufacturing of their second antibody with BioInvent demonstrates their
 continued confidence in our expertise.  We look forward to extending the
 excellent collaboration we already have with Antisoma."
 
     For further information, see http://www.antisoma.com or
 http://www.bioinvent.com
 
 

SOURCE Antisoma plc
    LONDON and LUND, Sweden, April 11 /PRNewswire/ -- Antisoma plc (LSE:ASM,
 EASD:ASOM) and BioInvent International AB today announce an agreement for the
 production of muBC-1, a murine monoclonal antibody.  muBC-1 will be used by
 Antisoma to develop a radiolabelled product, AngioMab, which is a potential
 anti-angiogenic treatment for targeted cancer therapy.
     Under the agreement, BioInvent, through its subsidiary BioInvent
 Production AB, will carry out process development and GMP (Good Manufacturing
 Practice) production of the antibody ready for radiolabelling, to meet both
 European (EMEA) and US (FDA) standards for clinical studies.
     It is currently expected that AngioMab will start Phase I human clinical
 studies at the end of 2001.  The product will be initially developed for
 intracranial delivery to treat glioblastoma multiforme, an aggressive form of
 brain cancer.  These tumours are often unresponsive to chemotherapy and are
 usually treated by surgery and radiotherapy.  There is a significant need to
 improve the low response and poor survival rates following standard therapy.
     Commenting on the agreement, Glyn Edwards, Chief Executive of Antisoma,
 said:
     "We have worked with BioInvent for more than four years and are pleased to
 extend the collaboration to a second product.  BioInvent have manufactured
 clinical supplies for our Phase III ovarian cancer study with pemtumomab.
 With the ever increasing number of biologicals entering clinical trials, the
 development of a sound relationship with BioInvent and the securing of
 manufacturing capacity is paramount to our bringing new molecules forward for
 clinical trials.  Antisoma aims to have at least one more product in clinical
 development by the end of this year, and securing this agreement for AngioMab
 takes us a step closer to our goal. "
     Cristina Glad, President of BioInvent Production AB, added:
     "Antisoma's decision to place the order for process development and GMP
 manufacturing of their second antibody with BioInvent demonstrates their
 continued confidence in our expertise.  We look forward to extending the
 excellent collaboration we already have with Antisoma."
 
     For further information, see http://www.antisoma.com or
 http://www.bioinvent.com
 
 SOURCE  Antisoma plc